• AstraZeneca to present new cardiovascular data on Farxiga in type-2 diabetes at ACC 2019

    • March 12, 2019
    • Posted By : admin
    • 0 Comment
    •   44 views

    Data evaluating the cardiovascular (CV) effects of Farxiga (dapagliflozin), including hospitalisation for heart failure (hHF) in adults with type-2 diabetes (T2D) have been selected for late-breaking clinical trial and oral presentations at the American College of Cardiology’s (ACC) 68th Annual Scientific Session on 16-18 March. The data are the first sub-analyses from the Phase III DECLARE-TIMI 58 trial for Farxiga.

    AstraZeneca will also present the latest results from the Brilinta (ticagrelor) Phase III TREAT trial in patients with the most dangerous form of heart attack, ST-segment elevation myocardial infarction (STEMI), and a new heart failure analysis from CVD-REAL, the first large real-world evidence study of its kind evaluating the risk of all-cause death and hHF in patients with T2D receiving treatment with a SGLT2 inhibitor (SGLT2i), including Farxiga.

    Joris Silon, Senior Vice President, Cardiovascular, Renal and Metabolism, BioPharmaceuticals, said: “AstraZeneca is committed to addressing some of the most pressing health problems faced by patients with cardiovascular and metabolic diseases, by identifying and mitigating specific risks. This is particularly important in reducing the prevalence and burden of heart failure. This disease affects nearly 64 million people globally, and is an early and frequent complication in patients with type-2 diabetes.”

  44 views

You Might Also Like

No comments found

LEAVE COMMENT

Archive

Offers
error: Content is protected !!